To evaluate the IFNβ-1α effect on CTLA-4 and PD-L1 expression, we used PBMC samples of IFNβ-1α-treated MS patients and confirmed that both CTLA-4 and PD-L1 expression increases in these groups in comparison with naïve patients. The gene discussed is CD274; the disease is myeloid sarcoma.